Maarten Pieter Rozing

Maarten Pieter Rozing

Auto-generated profile, based on publicly available information

Maarten Pieter Rozing

The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Affective Disorders
Verified
Journal Article
Closed access
ACAngela Carlier
Angela Carlier
JBJohanna G. Berkhof
Johanna G. Berkhof
MRMaarten Rozing
Maarten Rozing
FBFilip Bouckaert
Filip Bouckaert
PSPascal Sienaert
Pascal Sienaert
EEEric van Exel
Eric van Exel

1 January 2019 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
MRM.P. Rozing
M.P. Rozing
RVRobert Veerhuis
Robert Veerhuis
RWR.G.J. Westendorp
R.G.J. Westendorp
PEP. Eikelenboom
P. Eikelenboom
MSM. Stek
M. Stek
EEE. van Exel
E. van Exel

7 July 2021 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
AMAmalie Elisabeth Moth
Amalie Elisabeth Moth
PHPernille Hølmkjær
Pernille Hølmkjær
AHAnne Holm
Anne Holm
MRMaarten Pieter Rozing
Maarten Pieter Rozing
GOGritt Overbeck
Gritt Overbeck
Background Behavioral and psychological symptoms of dementia are frequently experienced in the nursing home setting and place a substantial burden on patients, relatives, and nursing home staff. Despite guidelines recommending non-pharmacological treatments, psychotropic drugs are often prescribed to address these symptoms. This is the case despite their effects being limited, and there being a risk of side effects and adverse events for the patient. Several studies have aimed to reduce the use of psychotropic drugs, with varying results. The reasons behind these variations are not well understood. Objectives The objective of this systematic review was to investigate which factors nursing home general practitioners and nursing home staff experience as barriers or facilitators when attempting to deprescribe psychotropic drugs in nursing home residents. Methods We searched PubMed, EMBASE, psycINFO, Web of Science, and CINAHL between April and September 2020. An inductive method using thematic analysis of the qualitative findings was applied for the derivation of themes. Quantitative studies were included but described descriptively and separately. Results Of 8204 unique records, 14 studies were included in the review. Of these, nine were interview or focus group studies and five were survey studies. Thematic analysis resulted in five major themes identified as either facilitators or barriers or both: (1) ‘Operationality and routines’; (2) ‘Lack of resources and qualifications’; (3) ‘Patient-related outcomes’, which points to a strong belief in negative patient-related outcomes of discontinuation and a downplay of side effects of the medication; (4) ‘Policies’, including support and buy-in from nursing home leadership; and (5) ‘Collaboration’ between physicians and nursing home staff. Themes 1 and 4 consist of facilitators. Theme 2 consists of barriers. Theme 3 and 5 consist of both facilitators and barriers. Evaluation of closed-ended questions from the surveys supported the findings. Conclusions Deprescribing psychotropic drugs used for behavioral and psychological symptoms of dementia in nursing home residents is challenging. Resources need to be in place for deprescribing, as well as there being a focus on the positive patient-related outcomes of doing so. Managerial support, staff routines, and interprofessional collaboration are some factors facilitating the process, in addition to there being routines and systematic procedures in place allowing for operationality and a common understanding. Addressing these barriers and facilitators is necessary to ensure that deprescribing can be understood as meaningful and pursued among healthcare professionals in the nursing home setting.

3 September 2021 in Pilot and Feasibility Studies
Verified
Journal Article
Open access
PDF file
MRM. P. Rozing
M. P. Rozing
AJA. Jønsson
A. Jønsson
RKR. Køster-Rasmussen
R. Køster-Rasmussen
TDT. D. Due
T. D. Due
JBJ. Brodersen
J. Brodersen
OGon behalf of the SOFIA Study Group
on behalf of the SOFIA Study Group
Background: People with severe mental illness (SMI) have an increased risk of premature mortality, predominantly due to somatic health conditions. Evidence indicates that primary and tertiary prevention and improved treatment of somatic conditions in patients with SMI could reduce this excess mortality. This paper reports a protocol designed to evaluate the feasibility of a coordinated co-produced care program (SOFIA model, a Danish acronym for Severe Mental Illness and Physical Health in General Practice) in the general practice setting to reduce mortality and improve quality of life in patients with severe mental illness. Methods: The SOFIA pilot trial is designed as a cluster randomized controlled trial targeting general practices in two regions in Denmark. We aim to include 12 practices, each of which is instructed to recruit up to 15 community-dwelling patients aged 18 and older with SMI. Practices will be randomized by a computer in a ratio of 2:1 to deliver a coordinated care program or usual care during a 6-month study period. A randomized algorithm is used to perform randomization. The coordinated care program includes educational training of general practitioners and their clinical staff educational training of general practitioners and their clinical staff, which covers clinical and diagnostic management and focus on patient-centered care of this patient group, after which general practitioners will provide a prolonged consultation focusing on individual needs and preferences of the patient with SMI and a follow-up plan if indicated. The outcomes will be parameters of the feasibility of the intervention and trial methods and will be assessed quantitatively and qualitatively. Assessments of the outcome parameters will be administered at baseline, throughout, and at end of the study period. Discussion: If necessary the intervention will be revised based on results from this study. If delivery of the intervention, either in its current form or after revision, is considered feasible, a future, definitive trial to determine the effectiveness of the intervention in reducing mortality and improving quality of life in patients with SMI can take place. Successful implementation of the intervention would imply preliminary promise for addressing health inequities in patients with SMI. Trial registration: The trial was registered in Clinical Trials as of November 5, 2020, with registration number NCT04618250. Protocol version: January 22, 2021; original version

27 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMaarten P. Rozing
Maarten P. Rozing
AMAnne Møller
Anne Møller
RARune Aabenhus
Rune Aabenhus
VSVolkert Siersma
Volkert Siersma
KRKatja Rasmussen
Katja Rasmussen
RKRasmus Køster-Rasmussen
Rasmus Køster-Rasmussen
To analyze the association between change in HbA1c during the first 6 years after diagnosis of Type 2 diabetes mellitus (Type 2 DM) and incident micro- and macrovascular morbidity and mortality during 13 years thereafter. This is an observational study of the participants in the intervention arm of the randomized controlled trial Diabetes Care in General Practice (DCGP) in Denmark. 494 newly diagnosed persons with Type 2 DM aged 40 years and over with three or more measurements of HbA1c during six years of intervention were included in the analyses. Based on a regression line, fitted through the HbA1c-measurements from 1 to 6 years after diabetes diagnosis, glycaemic control was characterized by the one-year level of HbA1c after diagnosis, and the slope of the regression line. Outcomes were incident diabetes-related morbidity and mortality from 6 to 19 years after diabetes diagnosis. The association between change in HbA1c (the slope of the regression line) and clinical outcomes were assessed in adjusted Cox regression models. The median HbA1c level at year one was 60 (IQR: 52–71) mmol/mol or (7.65 (IQR: 6.91–8.62) %). Higher HbA1c levels one year after diagnosis were associated with a higher risk of later diabetes-related morbidity and mortality. An increase in HbA1c during the first 6 years after diabetes diagnosis was associated with later microvascular complications (HR per 1.1 mmol/mol or 0.1% point increase in HbA1c per year; 95% CI) = 1.14; 1.05–1.24). Change in HbA1c did not predict the aggregate outcome ‘any diabetes-related endpoint, all-cause mortality, diabetes-related mortality, myocardial infarction, stroke, or peripheral vascular diseases. We conclude that suboptimal development of glycaemic control during the first 6 years after diabetes diagnosis was an independent risk factor for microvascular complications during the succeeding 13-year follow-up, but not for mortality or macrovascular complications.

4 September 2023 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
MRMaarten Pieter Rozing
Maarten Pieter Rozing
MWMarie Kim Wium‐Andersen
Marie Kim Wium‐Andersen
IWIda Kim Wium‐Andersen
Ida Kim Wium‐Andersen
TJTerese Sara Høj Jørgensen
Terese Sara Høj Jørgensen
MJMartin Balslev Jørgensen
Martin Balslev Jørgensen
MOMerete Osler
Merete Osler
Objective: To evaluate the risk of falls and fractures in users of benzodiazepines, Z‐drugs, or melatonin.Methods: We followed 699,335 adults with a purchase of benzodiazepines, Z‐drugs, or melatonin in the Danish National Prescription Registry between 2003 and 2016 for falls and fractures in the Danish National Patient Registry between 2000 and 2018. A self‐controlled case‐series analysis and conditional Poisson regression were used to derive incidence rate ratios (IRR) of falls and fractures during six predefined periods.Results: In total 62,105 and 36,808 adults, respectively, experienced a fall or fracture. For older adults, the risk of falls was highest during the 3‐month pre‐treatment period (IRRmen+70, 4.22 (95% confidence interval, 3.53–5.05), IRRwomen + 70, 3.03 (2.59–3.55)) compared to the baseline (>1 year before initiation). The risk continued to be higher in the later treatment periods. Contrarily, in men and women aged 40–69 years, the risk was only higher in the 3‐month pre‐treatment period. The incidence of falls among young men and women was slightly lower after initiation of sedating medication (treatment period, IRRmen15–39, 0.66 (0.50–0.86), IRRwomen15–39, 0.65 (0.51–0.83)). Analyses with fractures as outcome yielded similar results.Conclusions: Although falls and fractures occur more often in persons using sedative‐hypnotic medication, the higher risk of falls and fractures in the pre‐treatment period relative to the period directly after treatment, suggests that this association is better explained by other factors that elicited the prescription of this medication rather than the adverse effects of the sedative‐hypnotic medication.